Pascal Soriot, AstraZeneca CEO (Cole Burston/Bloomberg via Getty Images)

As­traZeneca's Lyn­parza-Imfinzi com­bo hits pri­ma­ry end­point in PhI­II en­dome­tri­al can­cer tri­al DUO-E

As­traZeneca’s block­buster can­cer drugs Imfinzi and Lyn­parza are step­ping in­to a new in­di­ca­tion — first-line en­dome­tri­al can­cer — and sig­nif­i­cant­ly im­proved one of the dual pri­ma­ry end­points, pro­gres­sion-free sur­vival, when com­bined with chemother­a­py, the com­pa­ny an­nounced Fri­day.

De­tailed da­ta weren’t in­clud­ed in this week’s high-lev­el re­sults from the DUO-E Phase III tri­al, but As­traZeneca says an Imfinzi-chemo com­bo fol­lowed up with ei­ther Imfinzi plus Lyn­parza or Imfinzi alone as a main­te­nance ther­a­py both showed a sta­tis­ti­cal­ly sig­nif­i­cant and clin­i­cal­ly mean­ing­ful im­prove­ment com­pared to plat­inum-based chemo alone in pa­tients with new­ly-di­ag­nosed ad­vanced or re­cur­rent en­dome­tri­al can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.